“A Repurposed Duo: Empagliflozin-Metformin Triggers a Metabolic Crisis in Cervical Cancer by Disrupting the Acyl-CoA/CoA Ratio via Dual Inhibition of PPAT and CPT1A”, J. Can. Res. Updates, vol. 14, pp. 247–265, Dec. 2025, doi: 10.30683/1929-2279.2025.14.26.